Rexulti Drug Class — Explained by Medical Evidence, Not Myths

Rexulti is the brand name for brexpiprazole, a prescription medicine in the atypical, or second-generation, antipsychotic drug class. It is also described as a serotonin-dopamine activity modulator because it affects several brain chemical signaling pathways rather than simply blocking one receptor.

Overview: What Drug Class Is Rexulti?

Rexulti is the brand name for brexpiprazole. The Rexulti drug class is called atypical antipsychotics, also known as second-generation antipsychotics. These medicines are used in several mental health and neurological care settings because they influence chemical messengers involved in mood, thinking, motivation, perception and behavior.

Brexpiprazole is often described more specifically as a serotonin-dopamine activity modulator. This means it has partial activity at certain dopamine and serotonin receptors and blocks activity at some other serotonin receptors. This receptor profile is different from that of older, first-generation antipsychotic medicines, although all medicines in these groups can have important side effects and require professional monitoring.

The word “antipsychotic” describes the medicine’s pharmacological class, not a person’s diagnosis or symptoms. A clinician may prescribe an atypical antipsychotic for conditions other than psychosis when there is evidence that it may help. The reason for treatment, expected benefits and possible risks should always be discussed individually.

Approved Uses and How Rexulti May Be Prescribed

Approved uses for Rexulti vary somewhat by country and may change as regulators review new evidence. In the United States, brexpiprazole is approved for schizophrenia in adults and certain adolescents, and as an add-on treatment for major depressive disorder in adults when an antidepressant alone has not provided enough improvement. It is also approved for agitation associated with dementia due to Alzheimer’s disease in adults.

For depression, Rexulti is generally not intended to replace an antidepressant without a clinician’s direction. Instead, it may be considered as an adjunctive, or add-on, medicine for selected people. Treatment for depression may also involve psychological therapies, sleep support, physical activity where appropriate and attention to coexisting health conditions.

Agitation in Alzheimer’s disease can include distress, irritability, verbal or physical outbursts, pacing or resistance to care. It deserves a careful assessment because pain, infection, poor sleep, medication effects, constipation, sensory difficulties and environmental stress can all contribute. Rexulti is not approved to treat dementia itself, memory loss or psychosis related to dementia.

Some clinicians may consider medicines outside their formal approved indications when evidence and individual circumstances support this approach. Such prescribing should be led by a qualified clinician who can explain why the medicine is being considered and how it will be monitored.

How Brexpiprazole Works in the Brain

Brain cells communicate using neurotransmitters, including dopamine and serotonin. These chemicals have wide-ranging roles in motivation, mood, reward, sleep, attention, movement and interpretation of experiences. Changes in these systems are associated with several psychiatric conditions, but they are only part of a complex biological, psychological and social picture.

Brexpiprazole partially activates dopamine D2 and D3 receptors and serotonin 5-HT1A receptors. Partial activation does not mean that the medicine simply “increases” or “decreases” a neurotransmitter. Rather, its effects depend on the receptor, the brain region and the level of natural signaling already present. It also blocks serotonin 5-HT2A receptors, a feature shared with many atypical antipsychotics.

This mechanism helps explain why Rexulti may be used in different clinical contexts, but receptor science cannot predict exactly how one individual will feel. Response can take time, and clinicians commonly assess changes in symptoms, sleep, energy, daily functioning, movement symptoms, weight and metabolic health over follow-up appointments.

Possible Side Effects and Important Safety Information

Like all prescription medicines, Rexulti can cause side effects, although not everyone experiences them. Commonly reported effects may include weight gain, increased appetite, restlessness or akathisia, headache, tiredness or sleepiness, dizziness, tremor, constipation and symptoms similar to a common cold. The likelihood and severity of side effects vary among individuals and may depend on other medicines and health conditions.

Akathisia is a particularly important symptom to recognize. It can feel like an uncomfortable inner restlessness, a need to move, pacing or difficulty sitting still. It may be mistaken for worsening anxiety or agitation. A person who develops this symptom should tell their prescriber promptly rather than changing the dose on their own.

Atypical antipsychotics can contribute to metabolic changes, including increased weight and changes in blood sugar or blood fats. Clinicians may check weight, waist measurement, blood pressure, glucose and lipid levels before or during treatment when appropriate. The medicine can also cause sleepiness or dizziness, so a person should use caution with driving, machinery and alcohol until they know how it affects them.

Brexpiprazole carries important regulatory warnings. Antipsychotic medicines are associated with increased mortality in older adults with dementia-related psychosis, and Rexulti is not approved for treating dementia-related psychosis. When used in connection with depression, antidepressant-related warnings about suicidal thoughts and behaviors in children, adolescents and young adults also apply. Close observation is especially important when treatment begins or changes.

Interactions, Monitoring and Taking Rexulti Safely

Rexulti is processed in the body mainly through enzymes called CYP2D6 and CYP3A4. Some medicines can slow or speed up these enzymes, which may raise or lower brexpiprazole levels. Examples include certain antidepressants, antifungal medicines, antibiotics, seizure medicines and herbal products. A prescriber or pharmacist should review all prescription drugs, over-the-counter medicines, vitamins and supplements.

Alcohol and other substances that cause drowsiness may increase sedation, dizziness or impaired judgment. People should also tell their clinician if they have diabetes, high cholesterol, heart disease, low blood pressure, seizures, swallowing difficulties, movement disorders, liver or kidney disease, or a history of compulsive behaviors such as problematic gambling or shopping.

Regular follow-up is a core part of safe treatment. The clinician may ask about mood, anxiety, unusual thoughts, movement changes, sleep, appetite and daily function. In some cases, laboratory testing or physical health checks are appropriate. Family members or caregivers can be helpful observers, particularly when the medicine is prescribed for agitation related to Alzheimer’s disease.

Rexulti should be taken exactly as prescribed. A person should not stop it, restart it after a break, double a missed dose or adjust it based only on day-to-day symptoms without contacting the prescriber. Sudden discontinuation can complicate assessment and may lead to the return of symptoms or other difficulties.

Myths and Facts About the Rexulti Drug Class

Myth: An antipsychotic is only used for psychosis. Fact: While this drug class is central to schizophrenia treatment, certain atypical antipsychotics also have evidence-based roles as add-on medicines for depression or for specific behavioral symptoms. The diagnosis, treatment goal and potential benefit should be clear before treatment starts.

Myth: Rexulti changes a person’s personality. Fact: The intended aim is to reduce clinically significant symptoms and improve day-to-day functioning, not to alter identity. However, unwanted emotional blunting, fatigue, restlessness or other changes should be discussed with the clinician, since they may indicate that the treatment plan needs review.

Myth: If a medicine is in the same class, it will have the same effects as every other medicine in that class. Fact: Atypical antipsychotics share some properties, but their receptor effects, approved uses, interactions and side-effect patterns differ. A medication that suits one person may not be suitable for another.

Myth: Improvement means monitoring is no longer needed. Fact: Ongoing reviews remain important because physical health, other medications, life circumstances and symptom patterns can change. A clinician can help balance benefits and risks over time.

When to Seek Medical Care

A person taking Rexulti should contact their prescribing clinician soon if they develop marked restlessness, new or worsening depression, severe sleepiness, fainting, unusual movements, significant weight changes, high thirst or urination, persistent vomiting, or symptoms that interfere with daily life. New urges or difficulty controlling behaviors, such as gambling, spending, eating or sexual behavior, should also be reported.

Urgent medical help is needed for thoughts of self-harm or suicide, severe confusion, chest pain, trouble breathing, a seizure, facial or tongue swelling, high fever with severe muscle stiffness, or a sudden major change in alertness or behavior. Caregivers should seek urgent assessment for an older person with dementia who develops sudden agitation, confusion or a change from their usual condition, as this may have a medical cause.

For people seeking coordinated mental health assessment, Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals can support diagnosis and treatment planning for international patients. Decisions about Rexulti should be made with a qualified doctor who understands the person’s medical history, current medicines and treatment goals.

Frequently asked questions